OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Flaherty Discusses the COLUMBUS Trial in Melanoma

June 12th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the COLUMBUS trial in patients with BRAF-mutant melanoma.

Dr. Usmani Discusses Immunotherapy in Hematologic Malignancies

June 12th 2018

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses immunotherapy in hematologic malignancies.

Dr. Rini Discusses the Findings of IMmotion151 in RCC

June 12th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma.

Dr. Flinn Discusses Hu5F9-G4 Plus Rituximab in NHL

June 12th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses Hu5F9-G4 (5F9) plus rituximab (Rituxan) in patients with non-Hodgkin lymphoma.

Dr. Roussos Torres on the Importance of Preclinical Models in HER2+ Breast Cancer

June 9th 2018

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

Dr. Ramalingam on Plasma EGFR Mutations as a Predictor of Response in NSCLC

June 9th 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses plasma EGFR mutations as a predictor of response to osimertinib (Tagrisso) in the AURA3 trial in non–small cell lung cancer.

Dr. Kolberg Discusses the LILAC Study of ABP 980

June 9th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the LILAC study of the biosimilar ABP 980.

Dr. Halabi Discusses Overall Survival Between African-American and Caucasian Men With mCRPC

June 8th 2018

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses overall survival between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell Lymphomas

June 8th 2018

Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.

Dr. Hilal Discusses Rituximab Maintenance in Mantle Cell Lymphoma

June 8th 2018

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab maintenance for patients with mantle cell lymphoma.

Dr. Maughan Discusses Abiraterone Plus Olaparib in mCRPC

June 7th 2018

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer.

Dr. Conroy Discusses Adjuvant mFOLFIRINOX in Pancreatic Cancer

June 7th 2018

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the results of an adjuvant modified FOLFIRINOX regimen (mFOLFIRINOX) in patients with pancreatic cancer.

Dr. Rischin Discusses Cemiplimab in Cutaneous Squamous Cell Carcinoma

June 7th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses cemiplimab in cutaneous squamous cell carcinoma.

Dr. Konecny Discusses the Role of PARP Inhibitors in Ovarian Cancer

June 7th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Valdes-Albini Discusses Trials in HER2+ Breast Cancer

June 7th 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

Dr. Patterson Discusses the Use of TKIs in Pediatric CML

June 7th 2018

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the use of tyrosine kinase inhibitors in the treatment of patients with chronic myeloid leukemia.

Dr. Yu on Comorbidities and Therapy Choice in Prostate Cancer

June 6th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.

Dr. Glaspy on Immunogenicity in Ovarian Cancer

June 6th 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.

Dr. Rao on Improving Methods of Early Detection of Ovarian Cancer

June 6th 2018

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses improving methods of early detection of ovarian cancer.

Dr. Ghosh on the Role of Bleomycin in Hodgkin Lymphoma

June 6th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the role of bleomycin in the treatment of patients with classical Hodgkin lymphoma.